Fragment-based drug design;
Biologics;
Off-shoring;
Outsourcing;
DRUG DISCOVERY;
DESIGN;
INHIBITORS;
BIOLOGICS;
BIG;
D O I:
10.1007/s10822-011-9451-z
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
Fragment-based lead discovery has undergone remarkable changes over the last 15 years. During this time, the pharmaceutical industry has changed dramatically as well, and continued evolution of the industry is assured. These changes present many challenges but also several opportunities for executing fragment-based drug design. This article will explore some of the more significant changes in the industry and how they may affect future discovery efforts related to fragment-based initiatives.
机构:
Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USAUniv Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA
Babaoglu, Kerim
Shoichet, Brian K.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USAUniv Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA